Neovacs (ALNEV)

Business description

Neovacs is a French biotechnology company developing immunotherapy treatments using its proprietary kinoid platform. It has one product in Phase II for rheumatoid arthritis and Crohn?s disease and another in Phase I/II for lupus.

Termination of coverage

Update | Pharmaceutical & healthcare | 17/05/2017

Edison Investment Research is terminating coverage on Neovacs (ALNEV). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news